Fineline Cube

Follow:
14435 Articles
Robo Medical Secures Tens of Millions in Funding for EndoFaster and EndoDreams Development
CompanyDeals

Robo Medical Secures Tens of Millions in Funding for EndoFaster and EndoDreams Development

CanSinoBio Receives NMPA Approval for Phase I/II Trial of Recombinant Polio Vaccine
CompanyDrug

CanSino Bio Receives NMPA Approval for Phase I/II Trial of Recombinant Polio Vaccine

Yifan Pharma's Generic Glycerol Phenylbutyrate Accepted for NMPA Review
CompanyDrug

Yifan Pharma’s Generic Glycerol Phenylbutyrate Accepted for NMPA Review

Hengrui Pharmaceuticals' SHR-8068 Gains NMPA Approval for NSCLC and Colorectal Cancer Trials
CompanyDrug

Hengrui Pharmaceuticals’ SHR-8068 Gains NMPA Approval for NSCLC and Colorectal Cancer Trials

Fosun Pharma's Zhejiang Xinghao Unit Initiates Phase Ib Study for COPD DPP-1 Inhibitor XH-S004
CompanyDrug

Fosun Pharma’s Zhejiang Xinghao Unit Initiates Phase Ib Study for COPD DPP-1 Inhibitor XH-S004

Legend Biotech's Carvykti Achieves USD 439 Million in Q2 2025 Sales
CompanyDrug

Legend Biotech’s Carvykti Achieves USD 439 Million in Q2 2025 Sales

Buchang Pharma Subsidiary Establishes Shaanxi Buchang MedData with Lingyishushu
CompanyDeals

Buchang Pharma Subsidiary Establishes Shaanxi Buchang MedData with Lingyishushu

Novartis Reports Double-Digit Growth in Q2 and 1H25, Driven by Key Brands
Company

Novartis Reports Double-Digit Growth in Q2 and 1H25, Driven by Key Brands

Takeda's Oveporexton Meets All Endpoints in Phase 3 Narcolepsy Type 1 Trials
CompanyDrug

Takeda’s Oveporexton Meets All Endpoints in Phase 3 Narcolepsy Type 1 Trials

PHASE Scientific Partners with Lumos Diagnostics to Launch FebriDx in US Respiratory Market
CompanyDeals

PHASE Scientific Partners with Lumos Diagnostics to Launch FebriDx in US Respiratory Market

Daiichi Sankyo and AstraZeneca Submit Enhertu Application for HER2-Positive Gastric Cancer in China
CompanyDrug

Daiichi Sankyo and AstraZeneca Submit Enhertu Application for HER2-Positive Gastric Cancer in China

Johnson & Johnson Reports 5.8% Sales Growth in 2025Q2, Increases Full-Year Guidance
Company

Johnson & Johnson Reports 5.8% Sales Growth in 2025Q2, Increases Full-Year Guidance